TI Pharma, Merck KGaA, Astellas Pharma and the Swiss Tropical and Public Health Institute (Swiss TPH) have entered into an international public-private partnership (PPP) to develop new pediatric formulation of praziquantel for the treatment ...
Tags: Pediatric Formulation, Swiss TPH, treatment of schistosomiasis
Premier, a healthcare group purchasing organization, has awarded a contract to Masimo to supply Masimo's SedLine brain function monitoring system, designed to help improve care of patients under anesthesia or sedation. The system, which ...
Tags: purchasing organization, brain function, monitoring system, anesthesia
Fluxion Biosciences has introduced an instrument to isolate rare circulating tumor cells (CTC) which disseminate from primary tumors and circulate throughout the peripheral blood. Using the proprietary microfluidic technology, the IsoFlux ...
Tags: CTC instrument, IsoFlux System, medical device, Class I medical device
Danone Research,Centre for Specialised Nutrition has deployed IDBS'data and process management platform E-WorkBook. This move is a part of Danone's plan to bring together its five international R&D communities. The deployment,which ...
PerkinElmer has teamed up with Massachusetts General Hospital (MGH) Pathology Department and Cancer Center to develop a new sequencing informatics system that can be used in advanced cancer research to profile genetic changes in tumors. ...
Tags: sequencing informatics system, automated sample, data analysis system
Cytochroma, a clinical stage specialty pharmaceutical company, has selected OmniComm Systems' eClinical Suite of applications for its two Phase III studies. OmniComm's eClinical Suite, including the EDC, CTMS, Safety, and Coding ...
Tags: Cytochroma, clinical stage, eClinical Suite, patient data, adverse events
Medical device research company Namsa has acquired The Integra Group, a preclinical and clinical research organization located near Minneapolis, US. The company with the acquisition of Integra aims to speed up the device research, ...
Athersys has received FDA orphan drug designation for its proprietary cell therapy, MultiStem, to treat Hurler's syndrome, also known as mucopolysaccharidosis type I or MPS-I. The orphan drug designation provides substantial potential ...
US distribution deal for spectral blood sensor 03 Jul 2012 PSS World Medical to market Masimo's latest multi-wavelength spot-checker for hemoglobin,pulse rate and perfusion index. Pronto-7 oximeter Masimo Corporation,the US ...
Tags: spectral blood sensor, medical sensor, PSS World Medical
Procedure for treating chronic atrial fibrillation,a condition that causes palpitations and fainting,features a laser balloon catheter. Green light for laser heart treatment? A follow-up study of 56 patients with chronic atrial ...
Tags: Heart Surgery, Laser, EAS
Teva Pharmaceutical Industries has reported that the Glatiramer Acetate Low-Frequency Administration (GALA) study evaluating a new dose of glatiramer acetate injection (GA) met its primary endpoint. The Phase III trial evaluated the ...
Tags: Teva Pharmaceutical Industries, Medicine, glatiramer acetate injection
Henry Schein Medical has entered into a collaboration agreement to distribute Masimo's new palm-sized Pronto-7 handheld device. In addition to Pronto-7, Henry Schein will distribute Pronto with rainbow technology to its US customer base ...
Tags: palm-sized Pronto-7 handheld device, Pronto-7 handheld device
Medtronic has presented two years of follow-up study results of its Resolute drug-eluting stent (DES). The study, which enrolled 878 standard risk2 diabetes patients and 1,903 patients without diabetes, will compare the clinical ...
Basilea Pharmaceutica has selected Dotmatics' suite of solutions for pre-clinical research informatics, which allows analyzing, registering and managing scientific data. The platform provides an electronic laboratory notebook for ...
Tags: Basilea Pharmaceutica, platform, chemistry and biology experiments
The US Food and Drug Administration (FDA) has approved Novartis Afinitor (everolimus) to treat patients with non-cancerous kidney tumors associated with tuberous sclerosis complex (TSC). The approval was based on the Phase III ...